Donor-specific antibodies (DSA) cause antibody-mediated rejection (AMR); however, their pathogenic role has not yet been adequately investigated after liver transplantation. The aim of our study was to analyse the clinical significance of DSA and complement-binding DSA for the prediction of AMR after liver transplantation. Our cohort included 120 liver recipients with assessed protocol biopsies one year post-transplant. All patients had defined HLA-specific and complement-binding (C1q + and C3d+) antibodies before and in regular intervals after transplantation. The incidence of DSA was evaluated in relation with clinical and histopathological data in the liver allografts. A higher occurrence of acute AMR was observed in recipients with preformed complement-binding DSA to HLA Class I antigens. Patients who developed chronic AMR had more frequently de novo-produced antibodies against HLA Class II antigens (P = 0.0002). A correlation was also found between de novo-formed C1q + and C3d+-binding antibodies to HLA Class II antigens and the development of chronic AMR (P = 0.043). Our study implies that preformed complement-binding DSA to HLA Class I antigens are related to increased risk of acute antibody-mediated rejection, while chronic AMR is more frequent in patients with de novo-produced antibodies to HLA Class II antigens after liver transplantation.

Department of Clinical and Transplantation Pathology IKEM Prague Czech Republic

Department of Hepatogastroenterology IKEM Prague Czech Republic

Department of Immunogenetics IKEM Prague Czech Republic

Department of Medical Statistics IKEM Prague Czech Republic

Transplantation Centre IKEM Prague Czech Republic

Zobrazit více v PubMed

Kim PT, Demetris AJ, O'Leary JG. Prevention and treatment of liver allograft antibody-mediated rejection and the role of the 'two-hit hypothesis'. Curr Opin Organ Transplant 2016; 21: 209.

Demetris AJ, Zeevi A, O'Leary JG. ABO-compatible liver allograft antibody-mediated rejection: an update. Curr Opin Organ Transplant 2015; 20: 314.

Hübscher SG. Antibody-mediated rejection in the liver allograft. Curr Opin Organ Transplant 2012; 17: 280.

Demetris AJ, Bellamy C, Hübscher SG, et al. 2016 Comprehensive update of the Banff Working Group on liver allograft pathology: introduction of antibody-mediated rejection. Am J Transplant 2016; 16: 2816.

Demetris AJ, Bellamy CO, Gandhi CR, Prost S, Nakanuma Y, Stolz DB. Functional immune anatomy of the liver-as an allograft. Am J Transplant 2016; 16: 1653.

Shin M, Moon HH, Kim JM, et al. Significance of true-positive and false-positive pretransplantation lymphocytotoxic crossmatch in primary liver allograft outcomes. Transplantation 2013; 95: 1410.

Wesson RN, Etchill EW, Garonzik-Wang J. Application and interpretation of histocompatibility data in liver transplantation. Curr Opin Organ Transplant. 2017; 22: 499.

Muro M, Moya-Quiles MR, Mrowiec A. Humoral alloresponse in liver transplantation: role of Human Leucocyte Antigens (HLA) antibodies. Curr Prot Pept Sci 2016; 17: 776.

Muro M, Marina L, Miras M, et al. Liver recipients harbouring anti-donor preformed lymphocytotoxic antibodies exhibit a poor allograft survival at the first year after transplantation: experience of one centre. Transpl Immunol 2005; 14: 91.

Musat AI, Agni RM, Wai PY, et al. The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation. Am J Transplant 2011; 11: 500.

Del Bello A, Congy-Jolivet N, Muscari F, et al. Prevalence, incidence and risk factors for donor-specific anti-HLA antibodies in maintenance liver transplant patients. Am J Transplant 2014; 14: 867.

O'Leary JG, Kaneku H, Jennings LW, et al. Preformed class II donor-specific antibodies are associated with an increased risk of early rejection after liver transplantation. Liver Transpl 2013; 19: 973.

Kaneku H, O'Leary JG, Banuelos N, et al. De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients. Am J Transplant 2013; 13: 1541.

O'Leary JG, Demetris AJ, Friedman LS, et al. The role of donor-specific HLA alloantibodies in liver transplantation. Am J Transplant 2014; 14: 779.

Del Bello A, Congy-Jolivet N, Danjoux M, Muscari F, Kamar N. Donor-specific antibodies and liver transplantation. Hum Immunol 2016; 77: 1063.

Vandevoorde K, Ducreux S, Bosch A, et al. Prevalence, risk factors, and impact of donor-specific alloantibodies after adult liver transplantation. Liver Transpl 2018; 24: 1091.

Kaneku H, O'Leary JG, Taniguchi M, Susskind BM, Terasaki PI, Klintmalm GB. Donor-specific human leukocyte antigen antibodies of the immunoglobulin G3 subclass are associated with chronic rejection and graft loss after liver transplantation. Liver Transpl 2012; 18: 984.

Wozniak LJ, Hickey MJ, Venick RS, et al. Donor-specific HLA antibodies are associated with late allograft dysfunction after pediatric liver transplantation. Transplantation 2015; 99: 1416.

O'Leary JG, Kaneku H, Banuelos N, Jennings LW, Klintmalm GB, Terasaki PI. Impact of IgG3 subclass and C1q-fixing donor-specific HLA alloantibodies on rejection and survival in liver transplantation. Am J Transplant 2015; 15: 1003.

Ducreux S, Guillaud O, Bosch A, et al. Monitoring efficiency of humoral rejection episode therapy in liver transplantation: any role for complement binding Luminex Single Antigen assays? Transpl Immunol 2016; 35: 23.

Kovandova B, Slavcev A, Sekerkova Z, Honsova E, Trunecka P. Antibody-mediated rejection after liver transplantation-relevance of C1q and C3d-binding antibodies. HLA 2018; 92(Suppl 2): 34.

Wiesner RH, Demetris AJ, Belle SH, et al. Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. Hepatology 1998; 28: 638.

Del Bello A, Neau-Cransac M, Lavayssiere L, et al. Outcome of liver transplant patients with preformed donor-specific anti-human leukocyte antigen antibodies. Liver Transpl 2020; 26: 256.

Legaz I, Boix F, López M, et al. Influence of preformed antibodies in liver transplantation. J Clin Med 2020; 9: 708.

Kozlowski T, Weimer ET, Andreoni K. C1q Test for identification of sensitized liver recipients at risk of early acute antibody-mediated rejection. Ann Transplant 2017; 22: 518.

Sapir-Pichhadze R, Curran SP, John R, et al. A systematic review of the role of C4d in the diagnosis of acute antibody-mediated rejection. Kidney Int 2015; 87: 194.

Seemayer CA, Gaspert A, Nickeleit V, Mihatsch MJ. C4d staining of renal allograft biopsies: a comparative analysis of different staining techniques. Nephrol Dial Transplant 2007; 22: 568.

Kozlowski T, Rubinas T, Nickeleit V, et al. Liver allograft antibody-mediated rejection with demonstration of sinusoidal C4d staining and circulating donor-specific antibodies. Liver Transpl 2011; 17: 357.

Watson R, Kozlowski T, Nickeleit V, et al. Isolated donor specific alloantibody-mediated rejection after ABO compatible liver transplantation. Am J Transplant 2006; 6: 3022.

Wozniak L, Venick R. Donor-specific antibodies following liver and intestinal transplantation: clinical significance, pathogenesis and recommendations. Int Rev Immunol 2019; 38: 106.

O’Leary JG, Kaneku H, Demetris AJ, et al. Antibody mediated rejection as a contributor to previously unexplained early liver allograft loss. Liver Transpl 2014; 20: 218.

Cousin VL, Rougemont AL, Rubbia-Brandt L, et al. Peripheral donor specific antibodies are associated with histology and cellular subtypes in protocol liver biopsies of pediatric recipients. Transplantation 2020; 104: 1633. https://doi.org/10.1097/TP.0000000000003099

Tokodai K, Miyagi S, Nakanishi C, et al. Association of post-transplant donor-specific HLA antibody with liver graft fibrosis during long-term follow-up after pediatric liver transplantation. Pediatr Transplant 2018; 22: e13169.

Everly MJ, Rebellato LM, Haisch CE, et al. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation 2013; 95: 410.